Clinical Trials on Regional Neuroblastoma

Total 5197 results

Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of DNA in Blood Samples From Patients With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of Specimens From Young Patients With Neuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States, Puerto Rico, Canada, Australia, New Zealand, Netherlands, Saudi Arabia, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions

Recurrent Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4 Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada
National Cancer Institute (NCI)

Completed

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

Pain | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Stage 4 Neuroblastoma | Neurotoxicity Syndrome

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma | Stage 1 Neuroblastoma | Stage 2 Neuroblastoma

United States, Canada, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Recurrent Neuroblastoma | Stage 4S Neuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma

United States, Canada, Australia, New Zealand
Medical University of Vienna

Terminated

The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

Macular Degeneration | Vascular Endothelial Growth Factor | Regional Blood Flow

Austria
Medical University of Vienna

Completed

Does Complement Factor H Gene Polymorphism Play a Role in the Regulation of Vascular Tone in the Choroid?

Macular Degeneration | Ocular Physiology | Regional Blood Flow | Genetic Polymorphism

Austria
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Stage 4S Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma | High Risk Neuroblastoma

United States, Canada, Puerto Rico, Australia, New Zealand
Stephan Grupp MD PhD
Children's Hospital of Philadelphia; University of Pennsylvania; Tmunity Therapeutics

Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2)

Refractory Neuroblastoma | High-risk Neuroblastoma | Relapsed Neuroblastoma

United States
University of Virginia
National Cancer Institute (NCI)

Unknown

Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
Nationwide Children's Hospital

Recruiting

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (STING)

Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Emory University

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (Aflac-NBL-2002)

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Clarity Pharmaceuticals Ltd

Recruiting

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Medical University of Vienna

Completed

An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects

Glaucoma | Macular Degeneration | Regional Blood Flow

Austria
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma | High-risk Neuroblastoma | Metastatic Neuroblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Ganglioneuroblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Children's Oncology Group
National Cancer Institute (NCI)

Completed

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States, Canada
Giselle Sholler
Van Andel Research Institute

Completed

A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
National Cancer Institute (NCI)

Terminated

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma

United States, Canada
M.D. Anderson Cancer Center
Elevar Therapeutics

Not yet recruiting

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Metastatic Olfactory Neuroblastoma | Recurrent Olfactory Neuroblastoma

United States
Medical University of Vienna

Completed

Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation

Regional Blood Flow

Austria
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Refractory Neuroblastoma | High Risk Neuroblastoma | Resectable Osteosarcoma

United States, Canada
University of Wisconsin, Madison
National Cancer Institute (NCI); Solving Kids' Cancer; Wade's Army; Midwest Athletes... and other collaborators

Withdrawn

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

Osteosarcoma | Neuroblastoma | Recurrent Neuroblastoma | Relapsed Neuroblastoma

United States
Cancer Research UK

Completed

A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma

Metastatic Neuroblastoma

United Kingdom
Yizhuo Zhang

Recruiting

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood. (CSIIT-Q36)

Neuroblastoma in Children

China
Samsung Medical Center
Ministry of Health, Republic of Korea

Unknown

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

High Risk Neuroblastoma
Belarusian Research Center for Pediatric Oncology...

Recruiting

DNA Vaccination Against Neuroblastoma

Relapsed Neuroblastoma

Belarus
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Neuroblastoma (NB)

United States
St. Jude Children's Research Hospital
Mayo Clinic

Terminated

A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma

Abdominal Neuroblastoma

United States
Baylor College of Medicine
New Approaches to Neuroblastoma Therapy Consortium

Completed

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

NEUROBLASTOMA

United States
BeiGene

Completed

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

High-risk Neuroblastoma

China
Memorial Sloan Kettering Cancer Center

No longer available

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

High Risk Neuroblastoma

United States
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
Giselle Sholler
Y-mAbs

Recruiting

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

High-risk Neuroblastoma

United States, Canada
Giselle Sholler
Beat NB Cancer Foundation; Because of Ezra; K C Pharmaceuticals Inc.

Completed

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Neuroblastoma Recurrent

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Recurrent Neuroblastoma

United States, Canada
National University Hospital, Singapore

Unknown

Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells (NKEXPGD2)

Neuroblastoma Recurrent

Singapore
National Cancer Institute (NCI)

Active, not recruiting

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Ganglioneuroblastoma | High Risk Neuroblastoma

United States, New Zealand, Australia

Clinical Trials on Regional Neuroblastoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations